Anti-PCSK9 Monoclonal Antibody Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET OVERVIEW

The antibodies are proteins generated by the body's immune system in response to specific antigens such as bacteria, viruses, parasites, and others identified as foreign. Monoclonal antibodies are protein produced by the immune system that targets a particular antigen in the body. Monoclonal antibodies are used in immunotherapy such as for diagnostic and therapeutic purposes. PCSK9 is proprotein convertase subtilisin/Kexin type 9, a member of the subtilisin family of serine proteases. It binds to the LDL receptor (LDLR), promoting LDLR degradation, thus resulting in less LDL sequestration and increased LDL-C levels. Numerous clinical trials have been done to demonstrate the efficacy of monoclonal antibodies against PCSK9 for lowering LDL-C levels. The targeted inhibition of PCSK9 would promote LDL catabolism and, thus, allow reduction of LDL-C levels.

MARKET SCOPE

The "Global Anti-PCSK9 Monoclonal Antibody Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the anti-PCSK9 monoclonal antibody market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading anti-PCSK9 monoclonal antibody market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

•  Based on type, the global anti-PCSK9 monoclonal antibody market is segmented into alizumab and evolocumab.
  
•  On the basis of application, the market is bifurcated into hypercholesterolemia, atherosclerotic cardiovascular disease and others.
  

MARKET DYNAMICS

Drivers

•  Increasing incidences of obesity globally, rising consumption of junk foods, and lack of regular exercise drive the anti-PCSK9 monoclonal antibody market.
  
•  Rising R&D activities focusing on monoclonal antibodies against PCSK9 and technological advancements boost the market growth.
  
•  Growing patients pool suffering from primary hypercholesterolemia and atherosclerotic cardiovascular disease fuel the market growth.
  

Restraints

•  Availability of alternative treatment methods.
  
•  High cost of monoclonal antibody.
  

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The anti-PCSK9 monoclonal antibody market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the anti-PCSK9 monoclonal antibody market in these regions.

IMPACT OF COVID-19 ON ANTI-PCSK9 MONOCLONAL ANTIBODY MARKET

COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The worldwide lockdown due to the pandemic has placed an economic burden on the healthcare sector. Therefore, research was limited, and researchers have to ensure the safety of trial participants, comply with good clinical practice (GCP), and minimize risks to trial integrity for the duration of the COVID-19 public health emergency. However, the market may witness growth in the future due to the companies rearranging their operations and recovering from the COVID-19 impact.

MARKET PLAYERS

The report covers key developments in the anti-PCSK9 monoclonal antibody market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from anti-PCSK9 monoclonal antibody market are anticipated to have lucrative growth opportunities in the future with the rising demand for anti-PCSK9 monoclonal antibody in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the anti-PCSK9 monoclonal antibody market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

•  Sanofi + Regeneron
  
•  Amgen
  
•  Creative Diagnostics
  
•  Thermo Fisher Scientific
  
•  Abnova
  
•  Dr. Reddy's
  
•  Merck
  
•  GeneTex
  
•  Novartis AG
  
•  PerkinElmer
  

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

Anti-PCSK9 Monoclonal Antibody Report Scope